Get the latest news, insights, and market updates on GOSS (Gossamer Bio, Inc.). Explore the news page 2 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.
Why Analysts Say Gossamer Bio’s Story Is Changing Ahead of Critical Clinical Milestones
Gossamer Bio's consensus analyst price target has recently risen from $8.86 to $9.50, which signals a more optimistic outlook among market observers. This adjustment comes as analyst sentiment grows increasingly positive ahead of important clinical milestones. Investors seeking insight on this evolving narrative should stay tuned for guidance on tracking further updates and expectations. Stay updated as the Fair Value for Gossamer Bio shifts by adding it to your watchlist or portfolio... Nov 14, 2025 - $GOSS
Gossamer Bio to Participate in Upcoming Investor Conferences
SAN DIEGO, November 07, 2025--Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that the Company will participate in the following investor conferences in November. Nov 7, 2025 - $GOSS
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, November 07, 2025--Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that the Compensation Committee of Gossamer’s Board of Directors approved the grant, effective November 5th, 2025, to six non-executive employees of non-qualified stock Nov 7, 2025 - $GOSS
Gossamer Bio: Q3 Earnings Snapshot
SAN DIEGO (AP) — Gossamer Bio Inc. GOSS) on Wednesday reported a loss of $48.2 million in its third quarter. On a per-share basis, the San Diego-based company said it had a loss of 21 cents. Nov 5, 2025 - $GOSS
Gossamer Bio (GOSS) Reports Q3 Loss, Tops Revenue Estimates
Gossamer Bio (GOSS) delivered earnings and revenue surprises of -10.53% and +118.76%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock? Nov 5, 2025 - $GOSS
Gossamer Bio Announces Third Quarter 2025 Financial Results and Provides Business Update
SAN DIEGO, November 05, 2025--Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced its financial results for the third quarter ended September 30, 2025, and provided a business update. Gossamer Bio and the Chiesi Group are jointly developing seralutin Nov 5, 2025 - $GOSS
Presenting on Emerging Growth Conference 87 Day 2 on October 23; Register to live stream
MIAMI, Oct. 22, 2025 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 87th Emerging Growth Conference on October 22 & 23, 2025. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting comp Oct 22, 2025 - $GOSS
Gossamer Bio Enters into Option Agreement to Acquire Respira Therapeutics and Its Lead Candidate, RT234, an Inhaled, On‑Demand Vardenafil for Pulmonary Hypertension
SAN DIEGO, September 25, 2025--Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced it has entered into an option agreement to acquire Respira Therapeutics (Respira) and its lead product candidate, RT234, an investigational inhaled vardenafil dry‑powd Sep 25, 2025 - $GOSS
We use cookies and similar technologies to collect and process data such as browsing activity or unique identifiers.
Selecting "Allow All" to help us understand site usage and improve the platform.
Choosing "Essential Cookies Only" enables only the cookies necessary for core site functions, such as staying logged in.
For more information, please see our Privacy Policy.
Continue with Google
Continue with Facebook
Continue with Microsoft
Continue with Apple